ELIC.ST

Elicera Therapeutics AB (publ) [ELIC.ST] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ELIC.ST Stock Summary

Top 10 Correlated ETFs

ELIC.ST

Top 10 Correlated Stocks

ELIC.ST

In the News

ELIC.ST Financial details

Company Rating
-
Market Cap
24.13M
Income
-16.4M
Revenue
3.18M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
13 Feb 2024
P/E
-6.69
Forward P/E
-
PEG
4.14
P/S
-
P/B
4.9
P/C
-
P/FCF
-8.03
Quick Ratio
3.7
Current Ratio
4.02
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.83
EPS next Y
-
EPS next Q
-
EPS this Y
-16.16%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-7.69%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-40%
Inst Own
-
Inst Trans
-
ROA
-55%
ROE
-56%
ROC
-0.75%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.0-7.24
52W High
-60.79%
52W Low
+174.5%
RSI
57
Rel Volume
-
Avg Volume
96.23K
Volume
Perf Week
15.09%
Perf Month
-4.69%
Perf Quarter
-56.84%
Perf Half Y
-48.69%
-
-
-
-
Beta
-0.594
-
-
Volatility
0.19%, 0.2%
Prev Close
-4.36%
Price
2.745
Change
-6.79%

Something similar

Top by Market Cap
V
VFINX
LLY.DE
TL0.DE
VTSAX
Top Correlated ETFs
CNBS
YOLO
MJ
MSOS
WEED
Top Correlated Stocks
HFFG
ALCO
BHMG.L
IOM.L
IGC
Similar Market Cap
DYSL
SYE
0602.HK
AREC.L
SAOCX

Company Profile

Healthcare Biotechnology
  • Volume Average 96.23K
  • Market Capitalization 24.13M
  • Employee 2
  • CEO Mr. Jamal El-Mosleh M.Sc.
  • Headquarters Gothenburg,SE
  • IPO Date 2021-06-11
  • Website https://www.elicera.com

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.